ALS Center of Excellence

Pranger ALS Clinic

  • Home
  • About
    • What Is ALS?
    • Scott L. Pranger
    • National Advisory Board
    • Faculty & Staff
    • ALS Center of Excellence Brochure
  • Clinic
    • Services
    • Your Visit to the ALS Clinic
    • Patient Portal
    • Durable Medical Equipment
    • Frequently Asked Questions
  • Research
    • Clinical Trials
    • Observational Studies
    • Stem Cell Trial
    • Our Publications
    • Participate in Research at U-M
  • News
  • Patient Care Guide
    • Nutrition
    • Living with ALS
    • Mobility & Independence
    • Patient & Family Support
  • Contact
  • NeuroNetwork
  • Make A Gift

OLLI Lecture: Stem Cell Therapy for Neurological Diseases – Where Are We Now

June 12, 2018

June 12, 2018

ANN ARBOR, Mich. — Dr. Eva Feldman, Russell N. DeJong Professor of Neurology and Director of the Program for Neurology Research & Discovery, was the featured presenter at the University of Michigan Osher Lifetime Learning Institute’s Distinguished Lecture Series on Tuesday (June 12). Held at Washtenaw Community College’s Towsley Auditorium, Dr. Feldman’s lecture was entitled “Stem Cell Therapy for Neurological Diseases: Where Are We Now.”

Dr. Feldman’s talk was broken down into four areas. She began with the economic potential of stem cell research and its importance to the State of Michigan. Over the past 20 years, the life science field has been growing steadily as a career path. She reviewed the history of embryonic stem cells and how government regulations have affected stem cell utilization in the United States and Michigan. The $100 million donation from Alfred Taubman was the catalyst for the University of Michigan Taubman Medical Research Institute, which has benefited Michigan’s University Research Corridor (MURC). The MURC promotes collaboration among the University of Michigan, Michigan State University, Wayne State University and other research entities.

Her second topic reviewed how embryonic stem cell lines are created and their medical potential. Dr. Feldman explained how neural progenitor cells, a more defined type of stem cell, are used when treating neurological diseases. In preclinical trials on rats with amyotrophic lateral sclerosis (ALS), these stem cells showed that they successfully developed into active nerves.

In 2010, the U.S. Food and Drug Administration (FDA) approved phase I trials of stem cell transplantation in human ALS patients. After showing the trial was safe, phase II began in 2013 with more patients added to confirm efficacy in the treatment. Dr. Feldman illustrated  the statistics that were used to measure results of patients from the trials as compared to a historical control group. The encouraging results of the phase I and II trials have led to plans for a phase III, which will involve a much larger patient population and multiple sites.

Lastly, Dr. Feldman discussed the future of stem cell research. Phase III of the ALS stem cell trial in humans can commence once funding is secured and the FDA gives final approval. Next, the University of Michigan Program for Neurology Research & Discovery hopes to begin preclinical trials using stem cell therapies to treat Alzheimer’s disease.

Dr. Feldman completed the morning with an enthusiastic question and answer period among the attendees.

Share this:

  • Facebook
  • Twitter
  • LinkedIn

Filed Under: News

ALS Brochure

ALS Brochure


COVID-19 Update

COVID-19 Resources

Join the National ALS Registry. With your help, we can advance research. Learn More.

Resources

Organizations

  • ALS Association
  • ALSA-Michigan Chapter
  • Ann Arbor Active Against ALS
  • ALSA-Northern Ohio Chapter
  • ALS of Michigan
  • National ALS Registry
  • Northeast ALS Consortium
  • Muscular Dystrophy Association

Services

  • Veterans Benefits
  • Social Security Benefits

Newsletter Signup

Subscribe to our mailing list for updates regarding our clinic and research

Useful Links

  • U-M Stem Cell Research
  • Center for Stem Cell Biology
  • Human Embryonic Stem Cell Research
  • Society for Stem Cell Research

RSS Research News

  • Research on aging expands at U-M with $15M in new grants
  • U-M to Conduct Clinical Trial to Test AstraZeneca COVID-19 Vaccine
  • Michigan Medicine and three other medical centers receive $7 million for COVID-19 outpatient convalescent plasma therapy trial

Contact Information

Michigan Medicine
1500 E. Medical Center Drive
Ann Arbor, MI 48109
Phone: 734-936-4000
Contact Michigan Medicine

Connect With Us

Copyright © 2021 Regents of the University of Michigan · Disclaimer · Privacy Statement

  • About UMHS
  • For Patients
  • For Health Professionals
  • For Researchers
  • Home
  • About
    ▼
    • What Is ALS?
    • Scott L. Pranger
    • National Advisory Board
    • Faculty & Staff
    • ALS Center of Excellence Brochure
  • Clinic
    ▼
    • Services
    • Your Visit to the ALS Clinic
    • Patient Portal
    • Durable Medical Equipment
    • Frequently Asked Questions
  • Research
    ▼
    • Clinical Trials
    • Observational Studies
    • Stem Cell Trial
    • Our Publications
    • Participate in Research at U-M
  • News
  • Patient Care Guide
    ▼
    • Nutrition
    • Living with ALS
    • Mobility & Independence
    • Patient & Family Support
  • Contact
  • NeuroNetwork
  • Make A Gift